TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07686120: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 286 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$518,584

Rescue Site Savings

+$330,008

Unlock Full NCT07686120 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07686120 Rescue Dossier →